El interés en corto de Revolution Medicines da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Revolution Medicines. Los datos de interés en corto se actualizan cada dos semanas.

Revolution Medicines (NASDAQ:RVMD) Bolsa, Informe de interés en corto

Revolution Medicines

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Revolution Medicines, Inc. - Common Stock

Revolution Medicines Inc

Benchmark analyst David Williams reiterates Littelfuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFUS#NASDAQ">LFUS</a>) from Hold to Hold.

News

Reiteration

Analyst Ratings

LFUS

Benchmark Reiterates Hold on Littelfuseto Hold

Blue Hat Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) reported quarterly losses of $(16.29) per share. This is a 83.37 percent increase over losses of $(97.93) per share from the same period last year. The company reported $18.72 million in sales this quarter. This is a 74.59 percent decrease over sales of $73.69 million the same period last year.

Earnings

BHAT

Blue Hat Interactive FY EPS $(16.29) Up From $(97.93) YoY, Sales $18.72M Down From $73.69M YoY

The U.S. economy unexpectedly contracted in the first quarter of 2025, posting its first negative growth reading since the second quarter of 2022 as Donald Trump's newly imposed trade tariffs sent shockwaves<a href="https://www.benzinga.com/news/econ-s"> through multiple sectors.</a>
Gross domestic product declined by 0.3% on an annualized basis during the January–March period, marking a sharp reversal from the 2.4% growth recorded in the final quarter of 2024. The reading fell short of analyst expectations, which had forecast a modest slowdown to 0.4% growth.
The decline in real GDP during the first quarter was mainly driven by a surge in imports—subtracted from GDP calculations—and a pullback in government spending. 
The U.S. economy posted the largest goods trade deficit ever in March, following the second- and third-largest monthly deficits on record in January and February, respectively, as importers accelerated foreign purchases in anticipation of tariffs. 
At the same time, spending reductions by the Elon Musk-led Department of Government Efficiency (DOGE) contributed further downward pressure on economic output.
&#8220;These movements were partly offset by increases in investment, consumer spending, and exports,&#8221; the Bureau of Economic Analysis wrote.
Price pressures intensified in the first quarter, reinforcing concerns over a potential stagflation scenario. 
The price index for gross domestic purchases rose 3.4%, accelerating from a 2.2% increase in the previous quarter. 
The personal consumption expenditures (PCE) price index—a key inflation gauge closely watched by the Federal Reserve—climbed 3.6%, up from 2.4% in the fourth quarter. 
Core PCE, which excludes volatile food and energy components, rose 3.5% after a 2.6% gain in the prior quarter, signaling persistent underlying inflation even as growth slows.
Earlier in the day, eurozone GDP data surprised to the upside, showing an expansion of 0.4% quarter-over-quarter, double the 0.2% growth economists had predicted.
<h3 class="wp-block-heading">Weak Labor Market Signals Emerge</h3>
In a separate economic release, Automatic Data Processing Inc. reported that U.S. private employers added just 62,000 jobs in April, the weakest figure since July 2024. 
That outcome marked a notable slowdown from March's 155,000 new jobs and missed economists' expectations of 108,000.
Service-providing industries added 34,000 jobs, while goods-producing industries added 26,000. 
&#8220;Unease is the word of the day. Employers are trying to reconcile policy and consumer uncertainty with a run of mostly positive economic data. It can be difficult to make hiring decisions in such an environment,&#8221; said ADP chief economist Nela Richardson. 
While ADP's private payroll data is not always a perfect proxy for the government's official employment numbers, the April report adds to signs of a cooling labor market. 
The Bureau of Labor Statistics will release its April Employment Situation Report on Friday, with nonfarm payrolls projected to rise by 130,000, down sharply from 228,000 in March.
<h3 class="wp-block-heading">Market Reactions</h3>
The U.S. dollar remained broadly steady across major currencies, with the euro-dollar exchange rate trading at 1.1370, down 0.1% on the day. 
U.S. Treasury yields snapped the seventh consecutive session of declines, with the 10-year yield inching up to 4.19%.
Stock futures suffered losses as investors speculated that signs of economic softness could weaken corporate profits. 
Futures on the S&amp;P 500 fell 0.8%, while contracts tied to the tech-heavy Nasdaq 100 tumbled 1.4% by 8:36 a.m. ET.
On Tuesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) closed 0.6% higher, fully recovering the losses incurred following Trump's tariff announcement on April 2.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45094024/us-futures-mixed-after-six-day-winning-streak-dont-sell-in-may-go-away-say-analysts">US Stock Futures Fall After Tuesday Rally, But History Favors Bulls: Markets Rose 9 Of Last 10 Mays, Says Expert</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

Tariffs Hit Hard As US Economy Shrinks For First Time Since 2022

Caterpillar CEO Reportedly Says On Conference Call That Potential Tariff Impact Has Increased Uncertainty

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major Indexes are lower following a contraction in Q1 GDP.

On April 28, 2025, 180 Life Sciences Corp. (the "Company", "we" and "us") entered into a Settlement and Mutual Release Agreement (the "Settlement Agreement") with Elray Resources, Inc. ("Elray"), and Luxor Capital, LLC ("Luxor"). Elray and Luxor are both controlled by Anthony Brian Goodman, the father of our director, Jay Goodman. The Settlement Agreement and related arrangements discussed below resolved certain disputes which had arisen between the parties relating to among other things, certain potential acquisitions.
&nbsp;
Pursuant to the Settlement Agreement: (a) the Company agreed to acquire all 1,318,000 of the shares of its common stock (the "Elray Shares") held by Elray, which were issued in March 2025, upon the conversion of 1,000,000 shares of Series B Convertible Preferred Stock which Elray then held (representing 23.1% of the Company's currently outstanding shares of common stock), in exchange for an aggregate settlement payment of $1 million, consisting of (i) $350,000 payable to Elray within five business days of the Settlement Agreement (the "Elray Payment") and (ii) $650,000 payable to Luxor ("Luxor Payment"). Amounts due to Luxor will be payable by way of 20% of proceeds raised by the Company in future capital raises until paid in full, but shall be paid no later than April 28, 2026; and (b) the Company, Elray, and Luxor exchanged mutual general releases from claims arising from prior negotiations and agreements, with limited exceptions for obligations under the Settlement Agreement and confidentiality requirements.
&nbsp;
In connection with the settlement, Elray agreed to deliver five stock powers authorizing cancellation of the Elray Shares, to be held in escrow and released proportionally at the option of the Company, as settlement payments are made, with all remaining shares canceled once the full amounts of the Elray Payment and Luxor Payment is made. The stock powers are to be released in tranches, with the stock power relating to the initial 461,300 Elray Shares eligible to be released from escrow upon payment of the Elray Payment, and the remaining four stock powers, each providing for the transfer of 214,175 shares, to be released upon the payment by the Company to Luxor of each additional $162,500. To date no Elray Shares have been returned to the Company or cancelled.
&nbsp;
Luxor also agreed to indemnify the Company against any claims brought by a third party related to certain prior negotiations involving an online casino asset acquisition.
&nbsp;
The Settlement Agreement included customary representations and warranties of the parties and confidentiality requirements. The Settlement Agreement also provides a restriction on Elray's sale or transfer of any of the Elray Shares.
&nbsp;
The Settlement Agreement also required Elray to enter into a Voting Agreement with the Company. Pursuant to the Voting Agreement, which was entered into on April 28, 2025, by Elray, the Company, and Blair Jordan, the Company's Chief Executive Officer, solely for the benefit of the Company, Elray agreed to vote any Elray Shares which it continued to hold, as recommended by the Board of Directors of the Company, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to April 28, 2026. In order to enforce the terms of the Voting Agreement, and solely for the benefit of the Company, Elray provided Mr. Jordan (or his assigns) an irrevocable voting proxy to vote the Elray Shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders.
&nbsp;
The Settlement Agreement and related transactions were approved by the Board of Directors of the Company, as well as the Company's Audit Committee, with Mr. Jay Goodman abstaining.
&nbsp;
The Settlement Agreement has no effect on the Company's ownership of, or rights associated with, certain source code and intellectual property relating to an online blockchain casino which the Company acquired from Elray in September 2024, nor Elray's ownership of warrants to purchase 3,000,000 shares of common stock with an exercise price of $1.68 per share.

Legal

ATNF

180 Life Sciences Enters $1M Settlement With Elray Resources and Luxor Capital To Resolve Acquisition Disputes, Reacquires 1.3M Shares Representing 23.1% Stake; Secures Indemnity From Luxor Over Casino Asset Negotiations

Red River Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRBI#NASDAQ">RRBI</a>) reported quarterly earnings of $1.52 per share which beat the analyst consensus estimate of $1.26 by 20.63 percent. This is a 31.03 percent increase over earnings of $1.16 per share from the same period last year. The company reported quarterly sales of $29.88 million which beat the analyst consensus estimate of $23.16 million by 29.00 percent. This is a 13.66 percent increase over sales of $26.29 million the same period last year.

Earnings Beats

RRBI

Red River Bancshares Q1 EPS $1.52 Beats $1.26 Estimate, Sales $29.88M Beat $23.16M Estimate

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

Price Target

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

HC Wainwright &amp; Co. analyst Robert Burns downgrades SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) from Buy to Neutral and lowers the price target from $74 to $47.

Downgrades

SWTX

HC Wainwright & Co. Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47

Americans spooked by headlines about Social Security's shaky finances are <a href="https://www.benzinga.com/personal-finance/25/04/45034325/americans-rush-to-claim-social-security-early-amid-growing-fears-of-cuts-and-agency-instability-under-trump-administration">racing to file claims</a> at 62, even though experts say the math still favors patience.
What To Know: The program's trustees warn that the retirement trust fund could run <a href="https://www.ssa.gov/policy/trust-funds-summary.html">dry by 2033</a>, after which only 79 percent of scheduled benefits would be paid. Yet financial planners argue that grabbing smaller checks today can backfire if you live into your 80s or 90s.
Fear is real: 64 percent of adults now <a href="https://www.allianzlife.com/about/newsroom/2025-Press-Releases/Americans-Are-More-Worried-About-Running-Out-of-Money-Than-Death?utm_source=chatgpt.com">worry more</a> about outliving their money than dying, with Social Security shortfalls ranking just behind inflation as the top stressor, according to a study by Allianz Life. Benefits replace only about 40 percent of <a href="https://www.ssa.gov/policy/docs/ssb/v68n2/v68n2p1.html">preretirement income</a> on average, and agency <a href="https://www.benzinga.com/news/25/04/44999167/social-security-payments-could-face-interruptions-in-may-warns-former-commissioner-martin-omalley-ne">staffing cuts</a> and long wait times have eroded public confidence.
See also: <a href="https://www.benzinga.com/markets/25/04/45091467/trump-can-either-have-his-cake-or-eat-it-economist-justin-wolfers-calls-out-presidents-fundamental-incoherence-on-trade-deals-and-tariffs">Trump Can Either Have His Cake Or Eat It, Economist Justin Wolfers Calls Out President&#8217;s &#8216;Fundamental Incoherence&#8217; On Trade Deals And Tariffs</a>
Still, the incentives to delay are sizable. Claiming at 62 trims monthly checks by <a href="https://www.ssa.gov/benefits/retirement/planner/agereduction.html">roughly 25 percent</a> for those whose full retirement age (FRA) is 66 and by 30 percent for an FRA of 67. Most retirees take the hit anyway, <a href="https://crsreports.congress.gov/product/pdf/R/R44670/14">according</a> to the Congressional Research Service. Waiting past FRA boosts benefits 8 percent per year until age 70 — a 24 percent to 32 percent jump that insures against <a href="https://www.ssa.gov/benefits/retirement/planner/delayret.html">longevity risk</a>.
Delaying is especially valuable for married couples and anyone worried about future inflation shocks, Vanguard researchers <a href="https://corporate.vanguard.com/content/dam/corp/research/pdf/claiming_social_security_early_spectrum_breakeven_longevity_risks.pdf">find</a>. Meanwhile, Donald Trump has repeated that he "won't cut current retirees' benefits," <a href="https://www.benzinga.com/government/25/04/45064937/donald-trump-threatens-to-veto-any-gop-bill-that-touches-medicaid-or-social-security-if-it-cuts-it-i-would-not-approve">reassuring older voters</a> even as Congress debates new taxes or modest trims for younger workers.
Bottom line, planners say: unless poor health shortens your horizon, every month you wait buys larger lifetime protection — and that may matter more than beating Washington's next funding fix.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/tech/25/04/45096452/mark-zuckerberg-denies-tilt-towards-donald-trump-says-big-tech-must-work-with-whoever-is-in-power-describes-last-decade-as-painful-maturation-process">Mark Zuckerberg Denies Tilt Towards Donald Trump, Says Big Tech Must Work With &#8216;Whoever&#8217; Is In Power, Describes Last Decade As &#8216;Painful Maturation Process&#8217;</a>

Personal Finance

Social Security Panic Is Premature, Experts Say: Delaying Claims Still Yields Bigger Checks Despite 2033 Trust-Fund Clock

Graham Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHC#NYSE">GHC</a>) reported quarterly earnings of $11.64 per share which beat the analyst consensus estimate of $11.29 by 3.1 percent. This is a 3.56 percent increase over earnings of $11.24 per share from the same period last year. The company reported quarterly sales of $1.17 billion which missed the analyst consensus estimate of $1.20 billion by 2.73 percent. This is a 1.12 percent increase over sales of $1.15 billion the same period last year.

Earnings Misses

Graham Hldgs Q1 Adj. EPS $11.64 Beats $11.29 Estimate, Sales $1.17B Miss $1.20B Estimate

Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) reported downbeat first-quarter 2025 <a href="https://www.benzinga.com/quote/SPOT/earnings">financial results on Tuesday</a>.
Spotify reported quarterly earnings of $1.13 per share, which missed the analyst consensus estimate of $2.33. The company reported quarterly sales of $4.41 billion (4.19 billion euros), up by 15% year-on-year, which beat the analyst consensus estimate of $4.20 billion.
Spotify clocked monthly average user (MAU) net additions of 3 million quarter-over-quarter to 678 million, which is in line with the guidance.
Spotify said it expects fiscal second-quarter 2025 revenue of $4.52 billion (4.3 billion euros) versus an analyst consensus estimate of $4.39 billion and total MAUs of 689 million.
Spotify shares fell 3.5% to close at $576.94 on Tuesday.
These analysts made changes to their price targets on Spotify following earnings announcement.
<ul>
<li>Rosenblatt analyst Barton Crockett maintained Spotify Technology with a Neutral rating and lowered the price target from $658 to $657.</li>
<li>Evercore ISI Group analyst Mark Mahaney maintained the stock with an Outperform rating and lowered the price target from $700 to $650.</li>
</ul>
Considering buying SPOT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234-1024x585.png" alt="" class="wp-image-894854" style="width:562px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

SPOT

Spotify Analysts Slash Their Forecasts After Q1 Earnings

Tradeweb Markets shares are trading higher. The company reported Q1 financial results.

Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) will report its second-quarter earnings on Wednesday. As the company reports after market hours, Wall Street expects $2.81 in EPS and <a href="https://www.benzinga.com/topic/semiconductors">$10.65 billion in revenues</a>.
The stock is down 11.44% over the past year, 4.40% YTD. Despite the decline, Qualcomm stock has been an outperformer in the chip sector so far this year. The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) is down over 15% YTD while the VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) is down 14%.
Wednesday's post-close earnings will put that momentum to the test. Beyond the headline numbers, Wall Street is laser-focused on two flashpoints: the potential impact of renewed Trump-era tariffs and any hints about Apple Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) <a href="https://benzinga.com/etfs/specialty-etfs/25/02/43888012/apples-in-house-modem-chip-sparks-qualcomm-concerns-3-etfs-with-key-exposure">expected phase-out of Qualcomm's modem chips</a>.
Let&#8217;s examine the charts for Qualcomm stock and how it currently compares to Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/25/04/45006138/smarter-cars-ahead-visteon-qualcomm-unveil-ai-cockpit-system">Visteon, Qualcomm Unveil AI Cockpit System For Smart Cars</a>
<h2 class="wp-block-heading">QCOM Stock Chart Mixed Ahead Of Q2 Earnings</h2>
Qualcomm stock is treading water ahead of earnings, with technical indicators painting a mixed picture for investors.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430"><img loading="lazy" decoding="async" width="627" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30064138/Screenshot-2025-04-30-at-4.10.36-PM.png" alt="" class="wp-image-894586" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30064138/Screenshot-2025-04-30-at-4.10.36-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30064138/Screenshot-2025-04-30-at-4.10.36-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430">Chart created using Benzinga Pro</a>
Qualcomm stock, at $146.88, is showing slight selling pressure and a relatively stagnant trend. However, short-term momentum leans bullish, with Qualcomm trading above its eight-day and 20-day simple moving averages ($142.78 and $140.07, respectively). This positioning typically suggests underlying strength and potential for a near-term move higher.
That said, medium- to longer-term signals flash caution. Qualcomm stock is still below its 50-day simple moving average of $151.38 and well beneath its 200-day simple moving average of $163.63 &#8211; both bearish indicators that imply resistance and a broader downtrend. 
The Moving Average Convergence Divergence (MACD) sits at a negative 1.61, reinforcing the bearish undertone, while the Relative Strength Index (RSI) at 52.22 signals a neutral stance, suggesting QCOM stock is neither overbought nor oversold. 
For investors, this setup suggests cautious optimism in the short term, but a clearer breakout or breakdown post-earnings could be needed to set the tone for what's next.
<h2 class="wp-block-heading">Qualcomm Analysts See Over 10% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/QCOM/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Qualcomm stock stands at a Buy currently with a price target of $193.41 a share. The latest analyst ratings from JPMorgan, Citigroup and TD Cowen imply a 10.39% upside for QCOM stock.
Price Action: Qualcomm stock closed the trading day Tuesday at $146.88, down 0.50%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/45094345/as-chinas-manufacturing-contracts-beijing-releases-defiant-video-calling-us-a-paper-tiger-and-vows-to-never-kneel-to-trumps-trade-war">As China&#8217;s Manufacturing Contracts, Beijing Releases Defiant Video Calling US A &#8216;Paper Tiger&#8217;</a></li>
</ul>
Image: Shutterstock

Technicals

Previews

Tech

AAPL

QCOM

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Qualcomm Stock Momentum Faces A Midweek Stress Test — Apple, Tariffs To Blame?

Pershing Square Holdco, L.P. ("Pershing Square"), the parent holding company of Pershing Square Capital Management, L.P. ("PSCM"), today announced that PSCM has further extended the term of its standstill agreement with Howard Hughes Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>) ("HHH") to facilitate ongoing discussions regarding the proposal previously announced by Pershing Square on February 18, 2025 and potential alternatives. On April 29, 2025, the term of the standstill agreement was extended from 5:00 p.m. (Eastern Time) on April 30, 2025 to 5:00 p.m. (Eastern Time) on May 30, 2025.

PSCM Extends Term Of Standstill Agreement With Howard Hughes Holdings To Facilitate Ongoing Discussions On Previous Proposal By Pershing Square And Potential Alternatives

Biotech

General

Oncocyte Announces Trial Progress, Completes Trial Design And Receives IRB Approval; Says Within Coming Weeks It Expects To Welcome Three Transplant Centers As Trial Participants

Better Choice Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#NYSE">BTTR</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRXH#NYSE">SRXH</a>) ("Better Choice" or the "Company"), a leading global health and wellness company, today announced completing its name change to SRx Health Solutions Inc. and the start of trading under the new ticker symbol ‘SRXH' today, Wednesday, April 30, 2025. The Company will continue trading on the NYSE American stock market under the new symbol, and no action is needed by current shareholders.
This name and ticker change follows the successful closing of the business combination between Better Choice Company and SRx Health, pursuant to which the combined company will emerge as a leading global health and wellness company committed to delivering better products and solutions for pets, people, and families.

BTTR

SRXH

Better Choice Company Announces Completion Of Name Change To SRx Health Solutions; Begins Trading Under The Ticker Symbol SRXH Today, Wednesday, April 30, 2025

Humana shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

Equitable Holdings shares are trading lower following a Q1 adjusted EPS miss.

JTAI

Jet.AI Signs LOI With Consensus Core To Pursue Development Of Two Hyperscale Data-Center Campuses

Press Releases

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

Revolution Medicines to Participate in March 2025 Investor Conferences

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Health Care

Revolution Medicines to Participate in April 2025 Investor Conferences

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Barbara Weber, M.D., Elected to ITM Supervisory Board

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Comments

Revolution Medicines

Interés en corto

Revolution Medicines (NASDAQ:RVMD) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL